- Home
- OUSTZ vs GLTO Comparison
OUSTZ vs GLTO Comparison
Compare OUSTZ & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUSTZ
- GLTO
- Stock Information
- Founded
- OUSTZ N/A
- GLTO 2011
- Country
- OUSTZ United States
- GLTO Denmark
- Employees
- OUSTZ 290
- GLTO N/A
- Industry
- OUSTZ Industrial Machinery/Components
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- OUSTZ Industrials
- GLTO Health Care
- Exchange
- OUSTZ Nasdaq
- GLTO Nasdaq
- Market Cap
- OUSTZ N/A
- GLTO 6.5M
- IPO Year
- OUSTZ N/A
- GLTO 2020
- Fundamental
- Price
- OUSTZ $0.08
- GLTO $4.95
- Analyst Decision
- OUSTZ
- GLTO Buy
- Analyst Count
- OUSTZ 0
- GLTO 1
- Target Price
- OUSTZ N/A
- GLTO $10.00
- AVG Volume (30 Days)
- OUSTZ N/A
- GLTO 17.9K
- Earning Date
- OUSTZ N/A
- GLTO 03-07-2025
- Dividend Yield
- OUSTZ N/A
- GLTO N/A
- EPS Growth
- OUSTZ N/A
- GLTO N/A
- EPS
- OUSTZ N/A
- GLTO N/A
- Revenue
- OUSTZ N/A
- GLTO N/A
- Revenue This Year
- OUSTZ N/A
- GLTO N/A
- Revenue Next Year
- OUSTZ N/A
- GLTO N/A
- P/E Ratio
- OUSTZ N/A
- GLTO N/A
- Revenue Growth
- OUSTZ N/A
- GLTO N/A
- 52 Week Low
- OUSTZ N/A
- GLTO $4.40
- 52 Week High
- OUSTZ N/A
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- OUSTZ N/A
- GLTO 43.07
- Support Level
- OUSTZ N/A
- GLTO $4.77
- Resistance Level
- OUSTZ N/A
- GLTO $5.35
- Average True Range (ATR)
- OUSTZ 0.00
- GLTO 0.37
- MACD
- OUSTZ 0.00
- GLTO -0.02
- Stochastic Oscillator
- OUSTZ 0.00
- GLTO 21.59
About OUSTZ Ouster Inc. Warrants
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.